Breaking News

Michael J. Fox on Parkinson's progress, M.D. versus ChatGPT, & potential tie between long Covid and menopause

October 20, 2023
Reporter, Morning Rounds Writer

Good morning. The room fell silent yesterday waiting for Michael J. Fox to appear on screen as a virtual STAT Summit guest to discuss research his Parkinson's foundation has sparked. More in an item below and in a post on our site, but this story of his initial diagnosis stayed with me: "I had a twitching pinky. That time, they said 70-80% of dopamine-producing cells are already gone. What happens in that time, that shadowy place?" Thanks to research advances, he said, "We can answer that question."

And in that spirit of discovery, here's who Priscilla Chan of the Chan Zuckerberg Initiative recruited to update the scientific knowledge she gained as an undergraduate: Steven Quake, a pioneer in single-cell sequencing at Stanford University, co-president of the  Biohub in the Bay Area, and "pretty qualified tutor," in Chan's words. Megan Molteni has more on Chan and Zuckerberg's aspirations to advance science.

stat summit summary

Michael J. Fox, doctors vs. ChatGPT, and what it feels like to sell your startup

STATSummit_167STAT

Here's what else Michael J. Fox had to say at the STAT Summit, as well as highlights from panels on an infectious disease doctor pitted against ChatGPT and a look behind the scenes at biotech founders making deals:

Michael J. Fox urges action: Here's the heart of the actor and advocate's message yesterday: "We don't want to be celebrated. We want to get things done." While acknowledging advances in Parkinson's research, he urged pharma executives attending the STAT Summit to take that progress further than what he's seen since being diagnosed at age 29. His foundation enabled research published in the Lancet Neurology in April that identified a biomarker for Parkinson's in a particular protein. A spinal tap is needed to detect the biomarker, but researchers called it "a game changer." 

When an audience member said she hopes her father can walk her down the aisle for her wedding, despite his recent Parkinson's diagnosis, Fox shared his own plans for his daughter's upcoming wedding: "I won't dance well, but I will dance." Read more from STAT's Theresa Gaffney.

ChatGPT is here to stay in medicine: It does pretty well on tests, correctly answering 80% of the questions on board exams, but how about in real life? STAT put ChatGPT to the test Wednesday, pitting the tool against Ann Woolley, infectious disease specialist at Brigham and Women's Hospital. Marc Succi, the innovation chair at Mass General, gave two patient scenarios to the tool while Woolley explained her own diagnoses.

In the first case, a 64-year-old man has fever, dizziness, headaches, and limb soreness. Woolley ultimately arrived at a diagnosis of Covid-19. GPT never explicitly said the diagnosis "Covid-19," but recommended ordering a host of tests, including a complete blood culture and a head CT scan. In the next, more complicated scenario, a man had respiratory failure, fever, and a previous fungal infection. GPT mirrored many of Woolley's diagnostic suggestions, and landed on the same primary diagnosis: an invasive fungal infection. STAT's Lizzy Lawrence has more.

How biotech deal-making really works: What does it feel like to run a biotech startup and then get "the call" — the one from the big pharma CEO who wants to acquire your company for billions of dollars? Here's what three people who know said Wednesday.
  • "Surreal," said Vlad Coric of Biohavenacquired by Pfizer in 2022 for $11.6 billion: "Imagine you're going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o'clock tonight." 
  • "Pride," said Athena Countouriotis of Turning Point Therapeutics, was acquired by BMS in 2022 for $4 billion: "The transaction will now mean that the sixth drug that my team would have brought to market is now going to be used in children and adults with cancer. "
  • "Impact," said Jacob Van Naarden, formerly of Loxo Oncology, which was acquired by Eli Lilly (where he is now) for $8 billion in 2019: "It starts with identifying opportunities where you think you can really add value rather than [making] pure financial transactions." Annalisa Merelli has more.


closer look

Teasing out a potential tie between long Covid and menopause

dial

Adobe

All through the pandemic, women have been reporting period disturbances after a Covid infection or after a Covid vaccination. But research specifically on long Covid and menopause is scarce, and mostly preliminary. Traci Kurtzer, a gynecologist and menopause specialist at the Northwestern Medicine Center for Sexual Medicine and Menopause, has been piecing this story together, writes STAT's Annalisa Merelli.  

"I've been experiencing absolutely a change in the number of women I'm seeing with earlier menopausal symptoms, and the severity of symptoms being quite a bit more intense than it used to be," she said. In one 42-year-old patient diagnosed with menopause, lab results found markers for autoimmune disease and Epstein-Barr virus. "I think that this is long Covid," said Kurtzer. Read more. 


reproductive health

How the fertility industry is feeling Dobbs' impact 

There was a shadow overhanging this year's annual meeting of the American Society of Reproductive Medicine in New Orleans. The U.S. Supreme Court's Dobbs decision not only ended 50 years of constitutional protection for abortion, but also fractured access to miscarriage management, cancer detection, and ectopic pregnancy treatments. And now the fertility industry is also feeling the ramifications.

In her plenary speech, Anita Allen, a professor of law and philosophy at the University of Pennsylvania, said fertility doctors are seeing more patients ask for pre-implantation genetic testing — a costly but unproven screening tool sold to improve the odds of having a healthy baby. Prospective parents may hope such measures minimize the chances of seeking an abortion. "Can you imagine being afraid to get pregnant?" Allen asked the audience. "To be so afraid that you invest thousands of dollars in pre-implantation testing in order to avoid getting caught up in the abortion prohibition mess?" STAT's Megan Molteni has more.


reproductive health

Live births more likely with gestational carriers

In other news from the field of assisted reproduction, a new research letter in JAMA reports that the chances of a live birth were higher with than without a gestational carrier — someone who carries a pregnancy for the intended parents after implantation of an embryo from those parents or a third party. That's significant because the use of gestational carriers has been rising, possibly because visibility and services are becoming more widespread for lesbian, gay, bisexual, transgender, and queer patients, along with changing laws about surrogacy.

The study looked at U.S. data between 2014 and 2020, when 4% of embryo transfers involved a gestational carriers. These transfers were more likely to result in pregnancy in a gestational carrier and in a live birth later. Twins were more likely when there was a gestational carrier, even after accounting for how many embryos were transferred. That might reflect the steep expenses prospective parents face with each cycle, the authors write.


Before you go: If you are Black, STAT and Word in Black invite you to take a survey about weight and body image.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Strapped down: Psychiatric patients are restrained at sky-high rates at this L.A. hospital, L.A. Times
  • CVS pulls cold medicines with phenylephrine as only active ingredient, Wall Street Journal
  • U.S. adults living alone may face higher risk of cancer death, study suggests, CNN
  • Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs, STAT
  • She's the queen of a pharma earworm, and the haters better watch out, Washington Post
  • Startup Laronde merges with another biotech in wake of data integrity issue, STAT

Thanks for reading! More Monday,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments